These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 25535382)
1. HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation. Jia H; Morris CD; Williams RM; Loring JF; Thomas EA Proc Natl Acad Sci U S A; 2015 Jan; 112(1):E56-64. PubMed ID: 25535382 [TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724 [TBL] [Abstract][Full Text] [Related]
3. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Thomas EA; Coppola G; Desplats PA; Tang B; Soragni E; Burnett R; Gao F; Fitzgerald KM; Borok JF; Herman D; Geschwind DH; Gottesfeld JM Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15564-9. PubMed ID: 18829438 [TBL] [Abstract][Full Text] [Related]
8. Epigenetics of Huntington's Disease. Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552 [TBL] [Abstract][Full Text] [Related]
9. LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease. Chopra V; Quinti L; Khanna P; Paganetti P; Kuhn R; Young AB; Kazantsev AG; Hersch S J Huntingtons Dis; 2016 Dec; 5(4):347-355. PubMed ID: 27983565 [TBL] [Abstract][Full Text] [Related]
10. The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice. Jia H; Wang Y; Morris CD; Jacques V; Gottesfeld JM; Rusche JR; Thomas EA PLoS One; 2016; 11(3):e0152498. PubMed ID: 27031333 [TBL] [Abstract][Full Text] [Related]
11. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Sadri-Vakili G; Bouzou B; Benn CL; Kim MO; Chawla P; Overland RP; Glajch KE; Xia E; Qiu Z; Hersch SM; Clark TW; Yohrling GJ; Cha JH Hum Mol Genet; 2007 Jun; 16(11):1293-306. PubMed ID: 17409194 [TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Huang PH; Chen CH; Chou CC; Sargeant AM; Kulp SK; Teng CM; Byrd JC; Chen CS Mol Pharmacol; 2011 Jan; 79(1):197-206. PubMed ID: 20959362 [TBL] [Abstract][Full Text] [Related]
13. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease. McFarland KN; Das S; Sun TT; Leyfer D; Xia E; Sangrey GR; Kuhn A; Luthi-Carter R; Clark TW; Sadri-Vakili G; Cha JH PLoS One; 2012; 7(7):e41423. PubMed ID: 22848491 [TBL] [Abstract][Full Text] [Related]
14. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Ryu H; Lee J; Hagerty SW; Soh BY; McAlpin SE; Cormier KA; Smith KM; Ferrante RJ Proc Natl Acad Sci U S A; 2006 Dec; 103(50):19176-81. PubMed ID: 17142323 [TBL] [Abstract][Full Text] [Related]
15. Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases. Sharma S; Taliyan R Pharmacol Res; 2015 Oct; 100():157-69. PubMed ID: 26254871 [TBL] [Abstract][Full Text] [Related]
16. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. Beconi M; Aziz O; Matthews K; Moumné L; O'Connell C; Yates D; Clifton S; Pett H; Vann J; Crowley L; Haughan AF; Smith DL; Woodman B; Bates GP; Brookfield F; Bürli RW; McAllister G; Dominguez C; Munoz-Sanjuan I; Beaumont V PLoS One; 2012; 7(9):e44498. PubMed ID: 22973455 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic therapy of cancer with histone deacetylase inhibitors. Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724 [TBL] [Abstract][Full Text] [Related]
18. Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes. Guiretti D; Sempere A; Lopez-Atalaya JP; Ferrer-Montiel A; Barco A; Valor LM Neurobiol Dis; 2016 May; 89():190-201. PubMed ID: 26851501 [TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. Ferrante RJ; Kubilus JK; Lee J; Ryu H; Beesen A; Zucker B; Smith K; Kowall NW; Ratan RR; Luthi-Carter R; Hersch SM J Neurosci; 2003 Oct; 23(28):9418-27. PubMed ID: 14561870 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Harrison IF; Dexter DT Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]